Conversely, depletion of NFIB in p53-mutated triple-negative breast cancer cell lines MDA-MB-435, HCC1806 and BT-20, promoted cell death, cell cycle arrest, and enhanced sensitivity to docetaxel, a first-line chemotherapeutic drug used in breast cancer treatment (Liu et al., 2019). Here, NFIB is linked to triple-negative breast carcinoma.